AstraZeneca_NNP Annual_JJ Report_NNP and_CC 130_CD Form_NN 20-F_JJ Information_NN 2005_CD ADDITIONAL_NNP INFORMATION_NNP FOR_IN US_NNP INVESTORS_NNP INTRODUCTION_NNP Capitalisation_NNP of_IN interest_NN New_NNP accounting_NN standards_NNS adopted_VBN The_DT accompanying_VBG consolidated_JJ Financial_NNP AstraZeneca_NNP does_VBZ not_RB capitalize_VB interest_NN under_IN AstraZeneca_NNP has_VBZ adopted_VBN the_DT provisions_NNS of_IN SFAS_NNP Statements_NNP included_VBD in_IN this_DT Annual_JJ Report_NNP IFRS_NNP ._.
US_NNP GAAP_NNP requires_VBZ interest_NN incurred_VBN No._NN ._.
123_CD R_NN Share-Based_NNP Payment_NN in_IN 2005_CD ._.
are_VBP prepared_VBN in_IN accordance_NN with_IN IFRS_NNP as_IN as_IN part_NN of_IN the_DT cost_NN of_IN constructing_VBG property_NN ,_, SFAS_NNP No._NN ._.
123_CD R_NN requires_VBZ compensation_NN cost_NN adopted_VBN by_IN the_DT EU_NNP ._.
There_EX are_VBP certain_JJ significant_JJ plant_NN and_CC equipment_NN to_TO be_VB capitalized_VBN and_CC related_VBN to_TO share-based_JJ payments_NNS to_TO be_VB recognized_VBN differences_NNS between_IN IFRS_NNP and_CC US_NNP GAAP_NNP amortised_VBD over_IN the_DT life_NN of_IN the_DT asset_NN ._.
AstraZeneca_NNP has_VBZ which_WDT affect_VBP AstraZenecas_NNP net_JJ income_NN and_CC followed_VBD the_DT transitional_JJ arrangements_NNS for_IN shareholders_NNS equity_NN and_CC ,_, on_IN pages_NNS 130_CD to_TO Deferred_JJ taxation_NN modified_VBD retrospective_JJ application_NN in_IN adopting_VBG 136_CD ,_, additional_JJ information_NN under_IN US_NNP GAAP_NNP Under_IN IFRS_NNP ,_, full_JJ provision_NN for_IN deferred_VBN taxation_NN SFAS_NNP No._NN ._.
123_CD R._NNP As_IN a_DT consequence_NN ,_, the_DT is_VBZ set_VBN out_RP as_IN follows_VBZ :_: is_VBZ made_VBN although_IN there_EX are_VBP a_DT number_NN of_IN 2004_CD comparative_JJ US_NNP GAAP_NNP income_NN before_IN different_JJ bases_NNS from_IN US_NNP GAAP_NNP on_IN which_WDT this_DT tax_NN has_VBZ been_VBN reduced_VBN by_IN $_$ 147m_CD with_IN a_DT related_JJ Summary_NNP of_IN differences_NNS between_IN IFRS_NNP and_CC calculation_NN is_VBZ made_VBN :_: for_IN example_NN ,_, the_DT elimination_NN tax_NN credit_NN of_IN $_$ 58m_CD and_CC the_DT shareholders_NNS US_NNP GAAP_NNP accounting_NN principles_NNS :_: page_NN 130_CD ._.
of_IN intra-group_JJ profit_NN on_IN inventories_NNS and_CC shareequity_NN at_IN 31_CD December_NNP 2004_CD increased_VBN by_IN Net_JJ income_NN :_: page_NN 131_CD ._.
based_VBN payment_NN transactions_NNS ._.
The_DT impact_NN in_IN 2003_CD was_VBD to_TO reduce_VB US_NNP GAAP_NNP condensed_JJ consolidated_JJ is_VBZ provided_VBN on_IN a_DT full_JJ liability_NN basis_NN under_IN US_NNP GAAP_NNP ,_, income_NN before_IN tax_NN by_IN $_$ 154m_CD with_IN a_DT related_JJ tax_NN statement_NN of_IN operations_NNS :_: page_NN 131_CD ._.
which_WDT requires_VBZ deferred_VBN tax_NN assets_NNS to_TO be_VB credit_NN of_IN $_$ 23m_CD and_CC increase_VB shareholders_NNS US_NNP GAAP_NNP statement_NN of_IN comprehensive_JJ recognized_VBN without_IN a_DT valuation_NN allowance_NN equity_NN at_IN 31_CD December_NNP 2003_CD by_IN $_$ 105m_CD ._.
income_NN :_: page_NN 132_CD ._.
if_IN their_PRP$ realisation_NN is_VBZ considered_VBN to_TO be_VB more_RBR Stock-based_JJ compensation_NN :_: page_NN 132_CD ._.
likely_RB than_IN not_RB ._.
New_NNP accounting_NN standards_NNS not_RB adopted_VBN Pension_NN and_CC post-retirement_NN benefits_NNS :_: In_IN November_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP page_NN 132_CD ._.
Pension_NN and_CC post-retirement_JJ benefits_NNS No._NN ._.
151_CD Inventory_NNP Costs_NNS to_TO clarify_VB the_DT Taxation_NNP :_: page_NN 134_CD ._.
IFRS_NNS requires_VBZ that_IN in_IN respect_NN of_IN defined_VBN benefit_NN accounting_NN for_IN abnormal_JJ amounts_NNS of_IN idle_JJ Shareholders_NNS equity_NN :_: page_NN 135_CD ._.
plans_NNS ,_, obligations_NNS are_VBP measured_VBN at_IN discounted_JJ facility_NN expense_NN ,_, freight_NN ,_, handling_VBG costs_NNS and_CC Acquired_VBN intangible_JJ assets_NNS and_CC goodwill_NN :_: fair_JJ value_NN whilst_NN plan_NN assets_NNS are_VBP recorded_VBN at_IN fair_JJ wasted_VBN material_NN spoilage_NN ._.
The_DT operating_NN and_CC financing_NN costs_NNS of_IN is_VBZ effective_JJ for_IN inventory_NN costs_NNS incurred_VBN during_IN US_NNP GAAP_NNP condensed_JJ consolidated_JJ such_JJ plans_NNS are_VBP recognized_VBN separately_RB in_IN the_DT fiscal_JJ years_NNS beginning_VBG after_IN 15_CD June_NNP 2005_CD ._.
statement_NN of_IN cash_NN flows_NNS :_: page_NN 136_CD ._.
income_NN statement_NN :_: service_NN costs_NNS are_VBP spread_VBN The_DT adoption_NN of_IN SFAS_NNP No._NN ._.
151_CD is_VBZ not_RB expected_VBN systematically_RB over_IN the_DT lives_NNS of_IN employees_NNS and_CC to_TO have_VB a_DT material_NN effect_NN on_IN the_DT results_NNS or_CC net_JJ DIFFERENCES_NNS BETWEEN_IN INTERNATIONAL_NNP financing_NN costs_NNS are_VBP recognized_VBN in_IN the_DT periods_NNS assets_NNS of_IN AstraZeneca_NNP ._.
AND_CC US_NNP ACCOUNTING_NNP PRINCIPLES_NNPS in_IN which_WDT they_PRP arise_VBP ._.
US_NNP GAAP_NNP adopts_VBZ a_DT similar_JJ Purchase_NN accounting_NN adjustments_NNS approach_VBP ._.
Under_IN IFRS_NNP ,_, actuarial_JJ gains_NNS and_CC In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP Under_IN IFRS_NNP ,_, the_DT merger_NN of_IN Astra_NNP and_CC Zeneca_NNP losses_NNS are_VBP permitted_VBN to_TO be_VB recognized_VBN No._NN ._.
152_CD Accounting_NN for_IN Real_NNP Estate_NNP Timeis_NNP accounted_VBD for_IN as_IN a_DT merger_NN of_IN equals_VBZ poolingimmediately_RB in_IN the_DT statement_NN of_IN recognized_VBN sharing_NN Transactions_NNS ,_, an_DT amendment_NN of_IN FASB_NNP of-interests_NNS as_IN a_DT result_NN of_IN the_DT business_NN income_NN and_CC expense_NN ._.
Under_IN US_NNP GAAP_NNP ,_, such_JJ Statements_NNP No._NN ._.
66_CD and_CC 67_CD which_WDT provides_VBZ that_IN combinations_NNS exemption_NN permitted_VBN by_IN IFRS_NNP 1_CD actuarial_JJ gains_NNS and_CC losses_NNS are_VBP permitted_VBN to_TO real_JJ estate_NN time-sharing_JJ transactions_NNS should_MD First-time_JJ Adoption_NN of_IN International_NNP Financial_NNP be_VB amortised_VBN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT be_VB accounted_VBN for_IN as_IN non-retail_JJ land_NN sales_NNS ._.
Under_IN US_NNP GAAP_NNP the_DT average_JJ remaining_VBG service_NN period_NN of_IN employees_NNS ._.
152_CD is_VBZ effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG merger_NN was_VBD accounted_VBN for_IN as_IN the_DT acquisition_NN A_DT minimum_JJ pension_NN liability_NN is_VBZ also_RB recognized_VBN after_IN 15_CD June_NNP 2005_CD ._.
The_DT adoption_NN of_IN SFAS_NNP of_IN Astra_NNP by_IN Zeneca_NNP using_VBG purchase_NN accounting_NN ._.
through_IN other_JJ comprehensive_JJ income_NN in_IN No._NN ._.
152_CD is_VBZ not_RB expected_VBN to_TO have_VB a_DT material_NN effect_NN Under_IN purchase_NN accounting_NN ,_, the_DT assets_NNS and_CC certain_JJ circumstances_NNS when_WRB there_EX is_VBZ a_DT deficit_NN on_IN the_DT net_JJ assets_NNS or_CC results_NNS of_IN AstraZeneca_NNP ._.
liabilities_NNS of_IN the_DT acquired_VBN entity_NN are_VBP recorded_VBN of_IN plan_NN assets_NNS relative_JJ to_TO the_DT accumulated_VBN at_IN fair_JJ value_NN ._.
As_IN a_DT result_NN of_IN the_DT fair_JJ value_NN benefits_NNS obligation_NN ._.
In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP exercise_NN ,_, increases_NNS in_IN the_DT values_NNS of_IN Astras_NNP No._NN ._.
153_CD Exchanges_NNS of_IN Non-monetary_JJ Assets_NNS ,_, property_NN ,_, plant_NN and_CC equipment_NN and_CC inventory_NN Intangible_JJ assets_NNS an_DT amendment_NN of_IN APB_NNP Opinion_NNP No._NN ._.
29_CD which_WDT were_VBD recognized_VBN and_CC values_VBZ attributed_VBN to_TO its_PRP$ Under_IN IFRS_NNP ,_, certain_JJ payments_NNS for_IN rights_NNS replaces_VBZ the_DT current_JJ exception_NN from_IN fair_JJ value_NN in-process_JJ research_NN and_CC development_NN and_CC to_TO compounds_NNS in_IN development_NN are_VBP capitalized_VBN ._.
measurement_NN for_IN non-monetary_JJ exchanges_NNS existing_VBG products_NNS ,_, together_RB with_IN appropriate_JJ Under_IN US_NNP GAAP_NNP ,_, these_DT payments_NNS are_VBP of_IN similar_JJ productive_JJ assets_NNS with_IN a_DT general_JJ deferred_JJ taxation_NN effects_NNS ._.
The_DT difference_NN between_IN generally_RB expensed_VBN ._.
exception_NN from_IN fair_JJ value_NN measurement_NN for_IN the_DT cost_NN of_IN investment_NN and_CC the_DT fair_JJ value_NN of_IN the_DT exchanges_NNS of_IN non-monetary_JJ assets_NNS that_WDT do_VBP assets_NNS and_CC liabilities_NNS of_IN Astra_NNP was_VBD recorded_VBN as_IN Financial_NNP instruments_NNS and_CC hedging_VBG activities_NNS not_RB have_VBP commercial_JJ substance_NN ._.
The_DT amount_NN allocated_VBN to_TO in-process_JJ Under_IN IFRS_NNP ,_, certain_JJ financial_JJ assets_NNS and_CC certain_JJ shall_MD be_VB applied_VBN prospectively_RB and_CC is_VBZ effective_JJ research_NN and_CC development_NN was_VBD ,_, as_IN required_VBN financial_JJ liabilities_NNS including_VBG derivatives_NNS are_VBP for_IN non-monetary_JJ asset_NN exchanges_NNS occurring_VBG by_IN US_NNP GAAP_NNP ,_, expensed_VBD immediately_RB in_IN the_DT first_JJ recognized_VBN at_IN fair_JJ value_NN :_: movements_NNS in_IN the_DT fair_JJ in_IN fiscal_JJ periods_NNS beginning_VBG after_IN 15_CD June_NNP 2005_CD ._.
reporting_VBG period_NN after_IN the_DT business_NN combination_NN ._.
value_NN may_MD be_VB recorded_VBN in_IN equity_NN or_CC through_IN The_DT adoption_NN of_IN SFAS_NNP No._NN ._.
153_CD is_VBZ not_RB expected_VBN Fair_NNP value_NN adjustments_NNS to_TO the_DT recorded_VBN amount_NN income_NN ,_, depending_VBG upon_IN their_PRP$ designation_NN ._.
to_TO have_VB a_DT material_NN effect_NN on_IN the_DT results_NNS or_CC net_NN of_IN inventory_NN were_VBD expensed_VBN in_IN the_DT period_NN the_DT Under_IN US_NNP GAAP_NNP ,_, marketable_JJ securities_NNS are_VBP assets_NNS of_IN AstraZeneca_NNP ._.
Additional_JJ amortisation_NN recognized_VBN at_IN fair_JJ value_NN ,_, with_IN movements_NNS in_IN fair_JJ and_CC depreciation_NN have_VBP also_RB been_VBN recorded_VBN in_IN value_NN taken_VBN to_TO a_DT separate_JJ component_NN of_IN equity_NN ._.
In_IN May_NNP 2005_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
154_CD respect_NN of_IN the_DT fair_JJ value_NN adjustments_NNS to_TO tangible_JJ Derivatives_NNS are_VBP also_RB measured_VBN at_IN fair_JJ value_NN with_IN Accounting_NNP Changes_NNS and_CC Error_NNP Corrections_NNPS and_CC intangible_JJ assets_NNS ._.
However_RB ,_, a_DT replacement_NN of_IN APB_NNP Opinion_NNP No._NN ._.
20_CD and_CC FASB_NNP financial_JJ liabilities_NNS are_VBP recorded_VBN at_IN amortised_JJ cost_NN ._.
154_CD requires_VBZ Under_IN IFRS_NNP ,_, up_RB until_IN 31_CD December_NNP 2002_CD ,_, retrospective_JJ application_NN of_IN prior_JJ periods_NNS goodwill_NN was_VBD required_VBN to_TO be_VB capitalized_VBN and_CC financial_JJ statements_NNS for_IN changes_NNS in_IN accounting_NN amortised_VBN ._.
154_CD applies_VBZ to_TO accounting_NN is_VBZ tested_VBN annually_RB for_IN impairment_NN but_CC not_RB periods_NNS beginning_VBG after_IN 15_CD December_NNP 2005_CD ._.
amortised_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, there_EX is_VBZ an_DT The_DT adoption_NN of_IN SFAS_NNP No._NN ._.
154_CD is_VBZ not_RB expected_VBN equivalent_JJ requirement_NN ,_, but_CC the_DT effective_JJ to_TO have_VB a_DT material_NN effect_NN on_IN the_DT results_NNS or_CC net_JJ date_NN was_VBD 1_CD January_NNP 2002_CD ._.
assets_NNS of_IN AstraZeneca_NNP ._.
Additional_JJ Information_NN for_IN US_NNP Investors_NNPS 131_CD NET_NNP INCOME_NNP As_IN a_DT result_NN of_IN the_DT significant_JJ difference_NN between_IN the_DT IFRS_NNP and_CC US_NNP GAAP_NNP treatment_NN of_IN the_DT combination_NN of_IN Astra_NNP and_CC Zeneca_NNP in_IN the_DT year_NN of_IN acquisition_NN ,_, and_CC in_IN the_DT results_NNS of_IN preceding_VBG periods_NNS ,_, condensed_JJ statements_NNS of_IN operations_NNS and_CC cash_NN flow_NN under_IN US_NNP GAAP_NNP have_VBP been_VBN prepared_VBN for_IN the_DT benefit_NN of_IN US_NNP investors_NNS ._.
The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT adjustments_NNS to_TO net_JJ income_NN and_CC shareholders_NNS equity_NN which_WDT would_MD have_VB been_VBN required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN IFRS_NNP ._.
2004 2003 2005_CD restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN for_IN the_DT period_NN under_IN IFRS_NNP 4,706_CD 3,664_CD 3,022_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Amortisation_NNP and_CC other_JJ acquisition_NN adjustments_NNS 1,019_CD 1,014_CD 952_CD Others_NNS Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 13_CD 1_CD 17_CD Deferred_VBN taxation_NN On_IN fair_JJ values_NNS of_IN Astra_NNP 283 283 266_CD Others_NNS 65_CD 55_CD 178_CD Pension_NN and_CC other_JJ post-retirement_JJ benefits_NNS expense_NN 74_CD 52_CD 23_CD Financial_NNP instruments_NNS 35_CD 61_CD 1_CD In-licensed_JJ development_NN intangibles_VBZ 29_CD 46_CD 21_CD Deferred_JJ income_NN recognition_NN 14_CD Unrealised_JJ losses_NNS on_IN foreign_JJ exchange_NN and_CC others_NNS 13_CD Net_JJ income_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 3,884_CD 2,951_CD 2,149_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NN US_NNP GAAP_NNP CONDENSED_NNP CONSOLIDATED_NNP STATEMENT_NNP OF_IN OPERATIONS_NNP 2004 2003 2005_CD restated_VBN restated_VBN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 23,950_CD 21,426_CD 18,849_CD Cost_NN of_IN sales_NNS 5,356_CD 5,152_CD 4,471_CD Distribution_NN costs_NNS 211 177 162_CD Research_NNP and_CC development_NN 3,429_CD 3,900_CD 3,493_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 8,783_CD 8,003_CD 7,036_CD Amortisation_NNP of_IN intangibles_NNS 1,009_CD 953_CD 881_CD Other_JJ income_NN 193 534 225_CD Operating_NN income_NN 5,355_CD 3,775_CD 3,031_CD Net_JJ interest_NN income_NN expense_NN 123_CD 1_CD 63_CD Income_NN from_IN continuing_VBG operations_NNS before_IN taxation_NN 5,478_CD 3,774_CD 3,094_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 1,594_CD 823_CD 945_CD Net_JJ income_NN from_IN continuing_VBG operations_NNS 3,884_CD 2,951_CD 2,149_CD Net_JJ income_NN for_IN the_DT year_NN 3,884_CD 2,951_CD 2,149_CD Weighted_VBN average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,617_CD 1,673_CD 1,709_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS 1_CD 23_CD Diluted_NNP weighted_JJ average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN accordance_NN with_IN US_NNP GAAP_NNP millions_NNS 1,618_CD 1,675_CD 1,712_CD Net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ 2.40_CD $_$ 1.76_CD $_$ 1.26_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NN AstraZeneca_NNP Annual_JJ Report_NNP and_CC 132_CD Form_NN 20-F_JJ Information_NN 2005_CD ADDITIONAL_NNP INFORMATION_NNP FOR_IN US_NNP INVESTORS_NNP CONTINUED_VBD US_NNP GAAP_NNP STATEMENT_NNP OF_IN COMPREHENSIVE_NNP INCOME_NNP 2004 2003 2005_CD restated_VBN restated_VBN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN for_IN the_DT year_NN 3,884_CD 2,951_CD 2,149_CD Exchange_NNP losses_NNS gains_NNS ,_, net_NN of_IN tax_NN 3,279_CD 2,106_CD 3,635_CD Other_JJ movements_NNS ,_, net_NN of_IN tax_NN 218_CD 20_CD 81_CD Total_JJ comprehensive_JJ income_NN 823_CD 5,077_CD 5,703_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NNP Other_JJ movements_NNS in_IN 2005_CD include_VBP a_DT reduction_NN in_IN the_DT minimum_JJ liability_NN under_IN SFAS_NNP No._NN ._.
87_CD Employers_NNS Accounting_NN for_IN Pensions_NNS from_IN $_$ 253m_CD to_TO $_$ 36m_CD ._.
Tax_NNP effects_NNS on_IN exchange_NN gains_NNS losses_NNS were_VBD $_$ 46_CD m_NN and_CC on_IN other_JJ movements_NNS $_$ 61m_CD ._.
The_DT cumulative_JJ exchange_NN gains_NNS and_CC losses_NNS net_NN of_IN tax_NN on_IN the_DT translation_NN of_IN foreign_JJ currency_NN financial_JJ statements_NNS under_IN US_NNP GAAP_NNP are_VBP set_VBN out_RP in_IN the_DT following_JJ note_NN :_: 2004 2003 2005_CD restated_VBN restated_VBN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN at_IN 1_CD January_NNP 4,342_CD 2,236_CD 1,399_CD Movement_NNP in_IN year_NN 3,279_CD 2,106_CD 3,635_CD Balance_NN at_IN 31_CD December_NNP 1,063_CD 4,342_CD 2,236_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NN The_DT cumulative_JJ total_NN of_IN other_JJ movements_NNS net_NN of_IN tax_NN at_IN 31_CD December_NNP 2005_CD was_VBD a_DT credit_NN of_IN $_$ 84m_CD 2004_CD charge_NN of_IN $_$ 134m_CD ,_, 2003_CD charge_NN of_IN $_$ 154m_CD ._.
STOCK-BASED_JJ COMPENSATION_NNP The_NNP Group_NNP has_VBZ adopted_VBN SFAS_NNP No._NN ._.
123_CD R_NN Share-Based_NNP Payments_NNS in_IN the_DT year_NN under_IN review_NN in_IN respect_NN of_IN share_NN options_NNS granted_VBN and_CC has_VBZ applied_VBN its_PRP$ provisions_NNS retrospectively_RB ._.
The_DT effects_NNS on_IN income_NN from_IN continuing_VBG operations_NNS ,_, income_NN before_IN tax_NN ,_, net_JJ income_NN and_CC basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN are_VBP set_VBN out_RP in_IN the_DT table_NN below_IN ._.
There_EX were_VBD no_DT impacts_NNS from_IN adoption_NN on_IN the_DT cash_NN flows_VBZ of_IN the_DT Group_NNP ._.
2005 2004 2003_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Income_NN from_IN continuing_VBG operations_NNS 128 147 154_CD Income_NN before_IN tax_NN 128 147 154_CD Net_JJ income_NN 100 107 111_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ 0.06_CD $_$ 0.06_CD $_$ 0.06_CD The_DT total_JJ compensation_NN cost_NN for_IN nonvested_JJ awards_NNS not_RB yet_RB recognized_VBN at_IN 31_CD December_NNP 2005_CD was_VBD approximately_RB $_$ 137m_CD and_CC is_VBZ expected_VBN to_TO be_VB recognized_VBN over_IN a_DT weighted_JJ average_JJ period_NN of_IN 21_CD months_NNS ._.
$_$ 143m_CD was_VBD received_VBN during_IN 2005_CD from_IN the_DT exercise_NN of_IN share_NN options_NNS and_CC similar_JJ instruments_NNS granted_VBN under_IN share-based_JJ payment_NN arrangements_NNS and_CC $_$ 3.9_CD m_NN tax_NN benefit_NN was_VBD realized_VBN from_IN share_NN options_NNS exercised_VBN during_IN the_DT year_NN ._.
PENSION_NN AND_CC POST-RETIREMENT_NN BENEFITS_NNS For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP ,_, the_DT pension_NN information_NN as_IN set_VBN out_RP in_IN Note_NN 23_CD in_IN respect_NN of_IN the_DT UK_NNP retirement_NN plans_NNS and_CC of_IN the_DT retirement_NN plans_NNS of_IN the_DT non-UK_JJ subsidiaries_NNS has_VBZ been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
132_CD Employers_NNS Disclosures_NNS about_IN Pensions_NNS and_CC Other_JJ Postretirement_NNP Benefits_NNPS ,_, an_DT amendment_NN of_IN FASB_NNP Statements_NNP No._NN ._.
These_DT plans_NNS comprise_VBP substantially_RB all_DT of_IN the_DT actuarial_JJ liabilities_NNS of_IN all_DT AstraZeneca_NNP retirement_NN plans_NNS ._.
The_DT changes_NNS in_IN projected_VBN benefit_NN obligations_NNS ,_, plan_NN assets_NNS and_CC details_NNS of_IN the_DT funded_JJ status_NN of_IN these_DT retirement_NN plans_NNS ,_, together_RB with_IN the_DT changes_NNS in_IN the_DT accumulated_VBN other_JJ post-retirement_JJ benefit_NN obligations_NNS ,_, under_IN SFAS_NNP No._NN ._.
132_CD are_VBP as_IN follows_VBZ :_: Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2005 2004 2003 2005_CD 2004_CD 2003_CD Change_NNP in_IN projected_VBN benefit_NN obligation_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Benefit_NNP obligation_NN at_IN beginning_NN of_IN year_NN 8,707_CD 7,416_CD 5,943_CD 249 242 210_CD Service_NNP cost_NN 256 229 171_CD 12_CD 11_CD 9_CD Interest_NN cost_NN 419 385 329_CD 14_CD 14_CD 14_CD Participant_NN contributions_NNS 31_CD 30_CD 26_CD 1_CD 11_CD Actuarial_JJ loss_NN gain_NN 764 328 545_CD 1_CD 3_CD 24_CD Settlement_NNP and_CC curtailment_NN 10_CD 5_CD Benefits_NNS paid_VBN 305 281 245_CD 15_CD 18_CD 19_CD Exchange_NNP 825 590 642_CD 3_CD 23_CD Benefit_NNP obligation_NN at_IN end_NN of_IN year_NN 9,047_CD 8,707_CD 7,416_CD 257 249 242_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS 133_CD PENSION_NN AND_CC POST-RETIREMENT_NN BENEFITS_NNS CONTINUED_VBD Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2005 2004 2003 2005_CD 2004_CD 2003_CD Change_NNP in_IN plan_NN assets_NNS $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Fair_NN value_NN at_IN beginning_NN of_IN year_NN 6,972_CD 5,905_CD 4,549_CD 217 195 133_CD Actual_JJ return_NN on_IN plan_NN assets_NNS 1,134_CD 565_CD 590_CD 13_CD 22_CD 35_CD Group_NNP contribution_NN 165 280 489_CD 13_CD 17_CD 43_CD Participant_NN contributions_NNS 31_CD 30_CD 26_CD 1_CD 1_CD Benefits_NNPS paid_VBD 305 281 245_CD 15_CD 17_CD 17_CD Exchange_NNP 629 473 496_CD 1_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN 7,368_CD 6,972_CD 5,905_CD 230 217 195_CD Funded_VBN status_NN of_IN plans_NNS 1,679_CD 1,735_CD 1,511_CD 27_CD 32_CD 47_CD Unrecognised_JJ net_JJ loss_NN 1,420_CD 1,644_CD 1,503_CD 32_CD 29_CD 36_CD Prior_RB service_NN cost_NN not_RB recognized_VBN 25_CD 15_CD 25_CD 8_CD 11_CD 9_CD Unrecognised_JJ net_JJ obligation_NN on_IN implementation_NN 1_CD 1_CD 19_CD 25_CD 29_CD 234_CD 77_CD 16_CD 16_CD 11_CD 9_CD Adjustments_NNS to_TO recognize_VB minimum_JJ liability_NN :_: Intangible_JJ assets_NNS 36_CD 39_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 36 217 260_CD Accrued_VBN benefit_NN liability_NN asset_NN 270 330 283_CD 16_CD 11_CD 9_CD At_IN 31_CD December_NNP 2005_CD ,_, the_DT projected_VBN benefit_NN obligation_NN ,_, accumulated_VBN benefit_NN obligation_NN and_CC fair_JJ value_NN of_IN the_DT plan_NN assets_NNS in_IN respect_NN of_IN the_DT pension_NN plans_NNS above_IN with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS were_VBD $_$ 6,984_CD m_NN ,_, $_$ 5,990_CD m_NN and_CC $_$ 5,566_CD m_NN ,_, 2004_CD $_$ 6,699_CD m_NN ,_, $_$ 5,800_CD m_NN and_CC $_$ 5,220_CD m_NN respectively_RB ._.
The_DT total_NN of_IN accumulated_VBN benefit_NN obligations_NNS for_IN the_DT pension_NN plans_NNS was_VBD $_$ 7,965_CD m_NN 2004_CD $_$ 7,443_CD m._FW The_DT measurement_NN date_NN for_IN the_DT plan_NN assets_NNS and_CC benefit_NN obligations_NNS set_VBN out_RP above_IN was_VBD 31_CD December_NNP 2005_CD ._.
Contributions_NNS to_TO the_DT plans_NNS in_IN 2006_CD are_VBP estimated_VBN to_TO be_VB $_$ 163m_CD ._.
Following_VBG an_DT employee_NN vote_NN in_IN December_NNP 2005_CD ,_, and_CC subject_JJ to_TO regulatory_JJ approval_NN ,_, the_DT Japanese_JJ defined_VBN benefit_NN pension_NN scheme_NN is_VBZ to_TO be_VB closed_VBN and_CC its_PRP$ assets_NNS and_CC obligations_NNS transferred_VBN to_TO a_DT defined_VBN contribution_NN scheme_NN ._.
The_DT curtailment_NN and_CC settlement_NN cost_NN ,_, to_TO be_VB recognized_VBN in_IN 2006_CD ,_, will_MD be_VB approximately_RB $_$ 35m_CD and_CC the_DT cash_NN payment_NN in_IN the_DT region_NN of_IN $_$ 100m_CD ._.
Assumed_VBN discount_NN rates_NNS and_CC rates_NNS of_IN increase_NN in_IN remuneration_NN used_VBN in_IN calculating_VBG the_DT projected_VBN benefit_NN obligations_NNS together_RB with_IN long_JJ term_NN rates_NNS of_IN return_NN on_IN plan_NN assets_NNS vary_VBP according_VBG to_TO the_DT economic_JJ conditions_NNS of_IN the_DT country_NN in_IN which_WDT the_DT retirement_NN plans_NNS are_VBP situated_VBN ._.
The_DT weighted_JJ average_NN rates_NNS used_VBN for_IN calculation_NN of_IN year_NN end_NN benefit_NN obligations_NNS and_CC forecast_NN benefit_NN cost_NN in_IN the_DT retirement_NN plans_NNS and_CC other_JJ benefit_NN obligations_NNS for_IN SFAS_NNP No._NN ._.
132_CD purposes_NNS were_VBD as_IN follows_VBZ :_: Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2005 2004 2003 2005_CD 2004_CD 2003_CD %_NN %_NN %_NN %_NN %_NN %_NN Discount_NNP rate_NN 4.8_CD 5.2_CD 5.5_CD 5.4_CD 5.7_CD 5.9_CD Long_JJ term_NN rate_NN of_IN increase_NN in_IN remuneration_NN 3.8_CD 3.9_CD 4.0_CD n_VBD a_DT n_NN a_DT n_NN a_DT Expected_VBN long_JJ term_NN return_NN on_IN assets_NNS 6.4_CD 6.8_CD 6.6_CD 6.5_CD 7.8_CD 7.8_CD The_DT Group_NNP has_VBZ assumed_VBN a_DT long_JJ term_NN rate_NN of_IN increase_NN in_IN healthcare_NN costs_NNS of_IN 9.9_CD %_NN ,_, reducing_VBG to_TO 4.9_CD %_NN ._.
Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2005 2004 2003 2005_CD 2004_CD 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ periodic_JJ cost_NN Service_NNP cost_NN present_JJ value_NN of_IN benefits_NNS accruing_VBG during_IN the_DT year_NN 256 229 171_CD 12_CD 11_CD 9_CD Interest_NN cost_NN on_IN projected_VBN benefit_NN obligations_NNS 419 385 329_CD 14_CD 14_CD 14_CD Expected_VBN return_NN on_IN assets_NNS 431 406 308_CD 17_CD 15_CD 14_CD Net_JJ amortisation_NN and_CC deferral_JJ 111_CD 76_CD 45_CD 3_CD 32_CD Net_JJ periodic_JJ cost_NN for_IN the_DT year_NN 355 284 237_CD 12_CD 13_CD 11_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC 134_CD Form_NN 20-F_JJ Information_NN 2005_CD ADDITIONAL_NNP INFORMATION_NNP FOR_IN US_NNP INVESTORS_NNP CONTINUED_VBD PENSION_NN AND_CC POST-RETIREMENT_NN BENEFITS_NNS CONTINUED_VBD The_DT weighted_JJ average_JJ allocation_NN of_IN pension_NN and_CC other_JJ post-retirement_JJ plan_NN assets_NNS was_VBD as_IN follows_VBZ :_: 2005 2004 2003_CD %_NN %_NN %_NN Equities_NNS 46.6_CD 48.2_CD 49.2_CD Bonds_NNS 37.5_CD 35.6_CD 48.8_CD Other_JJ 15.9_CD 16.2_CD 2.0_CD The_DT benefits_NNS expected_VBN to_TO be_VB paid_VBN in_IN the_DT future_NN are_VBP as_IN follows_VBZ :_: $_$ m_CD 2006 295 2007 306_CD 2008 319 2009 332_CD 2010 344 2011 2015_CD 1,909_CD TAXATION_NNP 2004 2003 2005_CD restated_VBN restated_VBN Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS Current_JJ tax_NN expense_NN Current_JJ year_NN 1,747_CD 1,349_CD 902_CD Adjustment_NNP for_IN prior_JJ years_NNS 112_CD 171_CD 26_CD Deferred_JJ tax_NN expense_NN Origination_NNP and_CC reversal_NN of_IN temporary_JJ differences_NNS 265_CD 355_CD 17_CD Total_JJ taxation_NN expense_NN in_IN the_DT income_NN statement_NN 1,594_CD 823_CD 945_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NN The_DT table_NN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN with_IN the_DT Groups_NNS actual_JJ charge_NN on_IN income_NN from_IN continuing_VBG operations_NNS ._.
2004 2003 2005_CD restated_VBN restated_VBN Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Income_NN from_IN continuing_VBG operations_NNS 5,478_CD 3,774_CD 3,094_CD Taxation_NNP charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN for_IN 2005_CD 30_CD %_NN for_IN 2004_CD ,_, 30_CD %_NN for_IN 2003_CD 1,644_CD 1,132_CD 928_CD Differences_NNS in_IN effective_JJ overseas_JJ tax_NN rates_NNS 147_CD 2_CD 41_CD Unrecognised_JJ deferred_JJ tax_NN asset_NN 25_CD 25_CD Items_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 136_CD 30_CD 111_CD Items_NNS not_RB chargeable_JJ for_IN tax_NN purposes_NNS 95_CD 71_CD 88_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 31_CD 171_CD 35_CD Exceptional_JJ items_NNS 124_CD Tax_NNP on_IN income_NN from_IN continuing_VBG operations_NNS 1,594_CD 823_CD 945_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NN In_IN 2005_CD ,_, claims_VBZ amounting_VBG to_TO $_$ nil_JJ 2004_CD $_$ nil_CD ,_, 2003_CD $_$ 95m_CD for_IN tax_NN relief_NN were_VBD made_VBN arising_VBG as_IN a_DT result_NN of_IN a_DT restructuring_NN of_IN the_DT AMI_NNP joint_JJ venture_NN in_IN 1998_CD ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT reliefs_NNS are_VBP adjusted_VBN against_IN the_DT goodwill_NN arising_VBG on_IN the_DT restructuring_NN and_CC included_VBD in_IN other_JJ adjustments_NNS ._.
Additional_JJ Information_NN for_IN US_NNP Investors_NNPS 135_CD SHAREHOLDERS_NNS EQUITY_NN 2004 2003 2005_CD restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD Total_JJ shareholders_NNS equity_NN under_IN IFRS_NNP 13,597_CD 14,404_CD 13,086_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Goodwill_NNP 13,504_CD 15,130_CD 14,342_CD Property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ assets_NNS 5,229_CD 6,988_CD 7,661_CD Others_NNS 58_CD 99_CD 55_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 241 254 255_CD Deferred_JJ taxation_NN On_IN fair_JJ value_NN of_IN Astra_NNP 1,629_CD 2,134_CD 2,313_CD Others_NNS 492 618 555_CD In-licensed_JJ development_NN intangibles_VBZ 112_CD 83_CD 38_CD Pension_NN and_CC other_JJ post-retirement_JJ benefits_NNS 1,483_CD 1,418_CD 1,212_CD Financial_NNP instruments_NNS 18_CD 22_CD 57_CD Others_NNS 3_CD 3_CD 3_CD Shareholders_NNS equity_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 31,894_CD 35,477_CD 33,759_CD Restated_VBN in_IN respect_NN of_IN SFAS_NNP 123_CD R_NN ACQUIRED_VBN INTANGIBLE_JJ ASSETS_NNS AND_CC GOODWILL_NN Details_NNS of_IN the_DT carrying_VBG amounts_NNS of_IN intangible_JJ assets_NNS and_CC past_JJ and_CC projected_VBD amortisation_NN expenses_NNS are_VBP set_VBN out_RP below_IN ._.
2005 2004 2003_CD Gross_NNP Gross_NNP Gross_NNP carrying_VBG Accumulated_NNP carrying_VBG Accumulated_NNP carrying_VBG Accumulated_NNP amount_NN amortisation_NN amount_NN amortisation_NN amount_NN amortisation_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Product_NNP rights_NNS 12,961_CD 7,011_CD 14,590_CD 6,744_CD 13,733_CD 5,274_CD Marketing_NNP and_CC distribution_NN rights_NNS 1,494_CD 1,043_CD 1,729_CD 1,043_CD 1,659_CD 831_CD Software_NNP 652 396 589 367_CD 462_CD 305_CD Others_NNS 437 310 460 360_CD 421_CD 329_CD Total_JJ 15,544_CD 8,760_CD 17,368_CD 8,514_CD 16,275_CD 6,739_CD Aggregate_NNP amortisation_NN expense_NN $_$ m_CD For_IN year_NN ended_VBD 31_CD December_NNP 2005_CD 1,287_CD For_IN year_NN ended_VBD 31_CD December_NNP 2004_CD 1,316_CD For_IN year_NN ended_VBD 31_CD December_NNP 2003_CD 1,245_CD Estimated_VBN amortisation_NN expense_NN For_IN year_NN ended_VBD 31_CD December_NNP 2006_CD 1,275_CD For_IN year_NN ended_VBD 31_CD December_NNP 2007_CD 1,187_CD For_IN year_NN ended_VBD 31_CD December_NNP 2008_CD 1,187_CD For_IN year_NN ended_VBD 31_CD December_NNP 2009_CD 1,187_CD For_IN year_NN ended_VBD 31_CD December_NNP 2010_CD 1,187_CD The_DT weighted_JJ average_JJ amortisation_NN period_NN in_IN respect_NN of_IN each_DT class_NN of_IN intangible_JJ asset_NN is_VBZ as_IN follows_VBZ :_: Product_NN rights_NNS 13_CD years_NNS Marketing_NNP and_CC distribution_NN rights_NNS 16_CD years_NNS Software_NNP 4_CD years_NNS Other_JJ 8_CD years_NNS AstraZeneca_NNP Annual_JJ Report_NNP and_CC 136_CD Form_NN 20-F_JJ Information_NN 2005_CD ACQUIRED_NNP INTANGIBLE_NNP ASSETS_NNPS AND_CC GOODWILL_NNP CONTINUED_VBD Goodwill_NNP The_NNP changes_NNS in_IN the_DT carrying_VBG amount_NN of_IN goodwill_NN for_IN the_DT three_CD years_NNS ended_VBN 31_CD December_NNP 2005_CD were_VBD as_IN follows_VBZ :_: $_$ m_CD Balance_NN as_IN at_IN 1_CD January_NNP 2003_CD 13,647_CD Acquired_VBN 1_CD Exchange_NNP movements_NNS 1,658_CD Balance_NN as_IN at_IN 31_CD December_NNP 2003_CD 15,306_CD Exchange_NNP movements_NNS 837_CD Balance_NN as_IN at_IN 31_CD December_NNP 2004_CD 16,143_CD Exchange_NNP movements_NNS 1,737_CD Balance_NN as_IN at_IN 31_CD December_NNP 2005_CD 14,406_CD US_NNP GAAP_NNP CONDENSED_NNP CONSOLIDATED_NNP STATEMENT_NNP OF_IN CASH_NNP FLOWS_NNP 2005 2004 2003_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS 6,919_CD 4,842_CD 3,416_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS 1,922_CD 862_CD 771_CD New_NNP non-current_JJ investments_NNS 12 117 120_CD Disposal_NNP of_IN property_NN ,_, plant_NN and_CC equipment_NN 87_CD 35_CD 38_CD Acquisitions_NNS and_CC disposals_NNS 355_CD 80_CD Capital_NNP expenditure_NN 942_CD 1,183_CD 1,515_CD Net_JJ cash_NN outflows_NNS from_IN investing_VBG activities_NNS 2,789_CD 1,772_CD 746_CD Net_JJ cash_NN flow_NN before_IN financing_VBG 4,130_CD 3,070_CD 2,670_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Equity_NNP dividends_NNS paid_VBD 1,717_CD 1,378_CD 1,222_CD Proceeds_NNS from_IN issue_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 143_CD 102_CD 47_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 3,001_CD 2,212_CD 1,154_CD Net_JJ increase_NN in_IN short_JJ term_NN borrowings_NNS 3_CD 2_CD New_JJ loans_NNS loans_NNS repaid_VBN 725_CD 345_CD Net_JJ cash_NN outflows_NNS from_IN financing_VBG activities_NNS 4,572_CD 2,761_CD 2,674_CD Decrease_NN increase_NN in_IN cash_NN 442_CD 309_CD 4_CD Cash_NN :_: At_IN 1_CD January_NNP 915 581 524_CD Decrease_NN increase_NN in_IN cash_NN 442_CD 309_CD 4_CD Exchange_NNP movements_NNS 12_CD 25_CD 61_CD At_IN 31_CD December_NNP 461 915 581_CD Interest_NN paid_VBN was_VBD $_$ 32m_CD in_IN 2005_CD 2004_CD $_$ 69m_CD ,_, 2003_CD $_$ 39m_CD ._.
